Staar Surgical
This article was originally published in The Gray Sheet
Executive Summary
David Bailey is appointed President and CEO December 20. Bailey, who formerly served as president of CIBA Vision's surgical business, plans to improve revenue growth by focusing on bundling products, such as toric and collamer IOLs with phacoemulsification technologies. Speaking at a Jan. 3 teleconference, Bailey did not address details of a December lawsuit by investor group NovaStaar which alleges mismanagement by Staar's board. Bailey is the fourth person to occupy the lead management position in the last 12 months. Board chairman Andrew Pollet has led the company as interim CEO and president since October, following the resignation of William Huddleston, who took over from dismissed Chairman, CEO, and President John Wolf in May 2000
You may also be interested in...
Staar Looking To AquaFlow, ICL To Drive Growth; Firm Cutting Workforce 25%
Staar Surgical's revised growth strategy hinges on cutting costs in its mature intraocular lens (IOL) business and sharpening its focus on the high growth, high margin glaucoma and refractive surgery markets, the firm announced Aug. 1.
Staar Looking To AquaFlow, ICL To Drive Growth; Firm Cutting Workforce 25%
Staar Surgical's revised growth strategy hinges on cutting costs in its mature intraocular lens (IOL) business and sharpening its focus on the high growth, high margin glaucoma and refractive surgery markets, the firm announced Aug. 1.
Staar Surgical
President and CEO David Bailey is elected chairman following the Jan. 11 death of Chairman Andrew Pollet, 49. Prior to Bailey's arrival on Dec. 20, Pollet served as Staar's interim president/CEO (1"The Gray Sheet" Jan. 8, 2001, In Brief)